Next Article in Journal
Target Low-Density Lipoprotein-Cholesterol and Secondary Prevention for Patients with Acute Myocardial Infarction: A Korean Nationwide Cohort Study
Next Article in Special Issue
Lung Aeration in COVID-19 Pneumonia by Ultrasonography and Computed Tomography
Previous Article in Journal
Early and Long-Term Outcomes after Propofol-and Sevoflurane-Based Anesthesia in Colorectal Cancer Surgery: A Retrospective Study
Previous Article in Special Issue
High versus Standard Intensity of Thromboprophylaxis in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis
 
 
Brief Report

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years

1
Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 7410001, Israel
2
Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel
3
Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel
4
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
5
Department of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan 5224213, Israel
6
Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
7
Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva 4941492, Israel
*
Author to whom correspondence should be addressed.
Academic Editors: Shitij Arora and Leonidas Palaiodimos
J. Clin. Med. 2022, 11(9), 2649; https://doi.org/10.3390/jcm11092649
Received: 24 March 2022 / Revised: 3 May 2022 / Accepted: 4 May 2022 / Published: 8 May 2022
(This article belongs to the Collection COVID-19: Clinical Advances and Challenges)
Both humoral and cellular anamnestic responses are significant for protective immunity against SARS-CoV-2. In the current study, the responses in elderly people before and after a fourth vaccine dose of BNT162b2 were compared to those of individuals immunized with three vaccine doses. Although a boost effect was observed, the high response following the third administration questions the necessity of an early fourth boost. View Full-Text
Keywords: SARS-CoV-2; BNT162b2; COVID-19 SARS-CoV-2; BNT162b2; COVID-19
MDPI and ACS Style

Bar-Haim, E.; Eliakim-Raz, N.; Stemmer, A.; Cohen, H.; Elia, U.; Ness, A.; Awwad, M.; Ghantous, N.; Moskovits, N.; Rotem, S.; Stemmer, S.M. Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years. J. Clin. Med. 2022, 11, 2649. https://doi.org/10.3390/jcm11092649

AMA Style

Bar-Haim E, Eliakim-Raz N, Stemmer A, Cohen H, Elia U, Ness A, Awwad M, Ghantous N, Moskovits N, Rotem S, Stemmer SM. Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years. Journal of Clinical Medicine. 2022; 11(9):2649. https://doi.org/10.3390/jcm11092649

Chicago/Turabian Style

Bar-Haim, Erez, Noa Eliakim-Raz, Amos Stemmer, Hila Cohen, Uri Elia, Asaf Ness, Muhammad Awwad, Nassem Ghantous, Neta Moskovits, Shahar Rotem, and Salomon M. Stemmer. 2022. "Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years" Journal of Clinical Medicine 11, no. 9: 2649. https://doi.org/10.3390/jcm11092649

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop